Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...